Financial Performance - The company's operating revenue for Q1 2023 was ¥23,955,839.36, representing a decrease of 3.80% compared to the same period last year[5] - The net profit attributable to shareholders was ¥3,015,115.00, down 23.86% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,283,466.89, a decline of 136.95%[5] - The basic and diluted earnings per share were both ¥0.03, reflecting a decrease of 25.00%[6] - The total operating profit for Q1 2023 was CNY 3,604,748, a decline of 18.7% from CNY 4,432,842 in the same period last year[20] - The total comprehensive income for Q1 2023 was CNY 3,015,115, reflecting a decrease from CNY 3,959,972 in the same quarter last year[21] - The net profit attributable to shareholders of the parent company for Q1 2023 was CNY 3,015,115, a decrease of 23.8% compared to CNY 3,959,972 in Q1 2022[21] Cash Flow - Cash flow from operating activities was -¥18,617,864.27, indicating a negative cash flow situation[6] - Cash flow from operating activities showed a net outflow of CNY 18,617,864, worsening from a net outflow of CNY 8,212,503 in Q1 2022[23] - Cash flow from operating activities in Q1 2023 was negative at -¥23,556,243.25, worsening from -¥12,895,985.53 in Q1 2022[32] - The company received cash from investment recovery amounting to ¥465,000,000.00 in Q1 2023, a substantial increase from ¥40,000,000.00 in Q1 2022[32] - The net cash flow from investment activities was negative at CNY -367,115,137, an improvement from CNY -707,982,663 in the previous year[24] - The net cash flow from investment activities was -$362.83 million, a decrease from -$705.89 million in the previous period[33] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,156,028,785.41, a decrease of 0.61% from the end of the previous year[6] - Total assets as of March 31, 2023, were RMB 1,156,028,785.41, slightly down from RMB 1,163,066,774.97 at the end of 2022[16] - Total liabilities decreased to RMB 31,723,218.83 from RMB 41,776,323.39, a reduction of 24.1%[17] - The total liabilities decreased to ¥16,768,864.59 in Q1 2023 from ¥27,268,328.38 in Q1 2022, indicating a significant reduction of 38.5%[27] - The company's total equity increased to RMB 1,124,305,566.58 from RMB 1,121,290,451.58, reflecting a growth of 0.2%[17] - The total equity as of Q1 2023 was ¥1,113,861,779.19, up from ¥1,109,800,236.71 in Q1 2022, reflecting a growth of 0.2%[27] Research and Development - The total R&D investment amounted to ¥3,275,505.96, which is 13.67% of the operating revenue, a slight decrease of 0.12 percentage points[6] - Research and development expenses for Q1 2023 were CNY 3,275,506, slightly down from CNY 3,435,324 in Q1 2022[20] - Research and development expenses for Q1 2023 were ¥3,275,617.75, slightly down from ¥3,435,324.49 in Q1 2022[29] Shareholder Information - The company reported a total of 8,017 common shareholders at the end of the reporting period[11] - The company's accounts receivable increased to ¥15,853,745.94 in Q1 2023 from ¥7,679,770.42 in Q1 2022, indicating a significant rise[26] - Accounts receivable rose to RMB 17,974,753.94 from RMB 7,679,770.42, indicating a significant increase of 134.5%[15] Strategic Focus - The company is focusing on new product development and market expansion strategies to improve future performance[19]

Financial Performance - The company's revenue for Q3 2022 was ¥71,224,053.26, representing a decrease of 1.15% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥32,308,050.17, down 2.46% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥27,095,838.11, a decline of 14.90% compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 was RMB 149,434,599.86, a decrease of 10.98% compared to RMB 167,970,821.17 in the same period of 2021[17] - The net profit for Q3 2022 was CNY 62,771,140.81, a decrease of 12.1% compared to CNY 72,158,230.66 in Q3 2021[18] - The total profit for Q3 2022 was CNY 73,163,332.95, a decrease of 12.5% compared to CNY 83,436,258.57 in the same quarter last year[18] - The net profit for the first three quarters of 2022 was CNY 63,106,277.36, down 9.06% from CNY 69,649,630.17 in the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,162,677,480.25, an increase of 188.58% compared to the end of the previous year[6] - The total assets of the company reached RMB 1,162,677,480.25, compared to RMB 402,891,055.95 at the end of 2021, indicating substantial growth[16] - The total liabilities increased to RMB 42,751,691.70 from RMB 33,261,983.99, marking a rise of 28.5%[15] - The total liabilities increased to CNY 27,146,500.32 in Q3 2022, compared to CNY 22,078,243.93 in Q3 2021, reflecting a growth of 23.5%[24] - The total equity rose significantly to CNY 1,107,720,567.08 in Q3 2022, compared to CNY 357,088,713.94 in Q3 2021, marking an increase of 210.4%[24] Shareholder Information - The equity attributable to shareholders at the end of the reporting period was ¥1,119,925,788.55, up 202.99% year-on-year[6] - The total number of ordinary shareholders at the end of the reporting period was 8,593[11] Research and Development - R&D expenses for the reporting period totaled ¥3,746,267.22, a decrease of 15.21% compared to the same period last year[6] - Research and development expenses decreased significantly to RMB 9,537,393.92 from RMB 14,967,192.02, a reduction of 36.2% year-over-year[17] - The company’s research and development expenses for the first three quarters of 2022 were CNY 9,675,989.56, down 46.6% from CNY 18,132,923.38 in the previous year[25] Cash Flow and Investments - The company's cash and cash equivalents as of September 30, 2022, were RMB 112,888,146.89, down from RMB 115,876,978.96 at the end of 2021[13] - Total cash inflow from investment activities was CNY 1,223,175,915.84, significantly higher than CNY 137,952,706.85 in the same period last year[20] - The net cash flow from investment activities was -CNY 753,906,332.87, worsening from -CNY 97,099,919.56 in the previous year[20] - The company reported a net cash outflow from investing activities of CNY -740,341,195.76 for the first three quarters of 2022, compared to CNY -85,121,985.45 in the previous year[30] Earnings Per Share - The basic earnings per share for Q3 2022 was ¥0.31, down 24.39% year-on-year[6] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.63, down from CNY 0.89 in the same period last year[19] Financial Ratios - The weighted average return on net assets decreased by 6.57 percentage points for the reporting period, primarily due to an increase in net assets from stock issuance and a decrease in net profit[9] - The company’s total liabilities to equity ratio increased to 24.5% in Q3 2022, compared to 61.8% in Q3 2021, indicating improved financial leverage[24]

Financial Performance - The company reported a total revenue of 100 million RMB for the first half of 2022, reflecting a year-on-year increase of 15%[13]. - The company's operating revenue for the first half of 2022 was ¥78,210,546.60, a decrease of 18.46% compared to the same period last year[19]. - The net profit attributable to shareholders for the same period was ¥30,463,090.64, down 21.96% year-on-year[21]. - The net profit after deducting non-recurring gains and losses decreased by 38.04% to ¥22,149,544.43[21]. - The net cash flow from operating activities increased by 99.80% to ¥21,313,947.74, attributed to increased sales collections and reduced cash expenditures due to pandemic restrictions[21]. - The company's net assets at the end of the reporting period grew by 194.25% to ¥1,087,617,738.38, primarily due to funds raised from the initial public offering[21]. - Total assets increased by 181.03% to ¥1,132,259,195.67 compared to the end of the previous year[21]. - Basic earnings per share decreased by 33.33% to ¥0.32, while diluted earnings per share also fell by the same percentage[20]. - The proportion of R&D investment to operating revenue was 7.40%, a decrease of 3.60 percentage points compared to the previous year[20]. - The weighted average return on net assets decreased by 8.48 percentage points to 4.00%[20]. Market and Product Development - User data showed an increase in the number of customers by 20%, reaching a total of 50,000 active users[13]. - The company plans to launch two new products in Q3 2022, aiming to capture a larger market share in the immunotherapy sector[13]. - Future outlook includes a projected revenue growth of 25% for the full year 2022, driven by new product launches and market expansion efforts[13]. - Market expansion strategies include entering two new provinces in China by the end of 2022[13]. - The company specializes in the production of antivenom and antitoxin products, with a focus on snake antivenom, tetanus antitoxin, and rabies antiserum, holding a unique position in the domestic market[28]. - The company’s main product, the anti-snake venom serum, is the only effective treatment for snakebite poisoning in China, with no domestic competitors[29]. - The company has achieved fourth-generation production standards for its main products, including the horse tetanus immunoglobulin and anti-viper venom serum[27]. - The horse tetanus immunoglobulin is the only product in China that has obtained drug registration and production licenses, certified by GMP[31]. - The anti-rabies serum provides immediate neutralization of the rabies virus, recommended for high-risk exposure cases alongside vaccination[34]. Research and Development - The company is investing 10 million RMB in R&D for new technologies related to antibody production[13]. - The company achieved a total R&D investment of ¥5,791,126.70, a decrease of 45.10% compared to ¥10,548,709.30 in the same period last year[47]. - R&D investment accounted for 7.40% of total revenue, down from 11.00%, representing a decrease of 3.60 percentage points[47]. - The company published two SCI papers related to the preparation and identification of horse antiserum against sea snake venom, indicating ongoing collaboration with military medical institutions[45]. - The company has developed a high-efficiency virus inactivation technology to ensure the safety of antiserum products, enhancing the production process[43]. - The company has established a comprehensive immune technology database to optimize immunization protocols, resulting in higher antibody yield and reduced variability[42]. - The company has applied modern column chromatography purification technology, significantly reducing adverse reactions and serum sickness incidence in antiserum production[44]. - The company has not made significant changes to its core technologies during the reporting period, maintaining its proprietary techniques for effective antivenom production[44]. - The company reported a total of 6 new patent applications during the reporting period, with a cumulative total of 29 applications and 12 granted patents[46]. - The company’s research and development activities were impacted by the pandemic, causing delays and interruptions in some projects[49]. Risk Factors and Challenges - Risk factors identified include potential regulatory changes that could impact product approvals and market access[4]. - The company attributed the decline in revenue to the impact of COVID-19 on market activities, particularly affecting customers engaged in outdoor and field operations[21]. - The company faces risks related to product safety, price control, and increasing market competition, which could impact future performance[66]. - The company faced risks related to the single product structure, primarily relying on snake antivenom serum and tetanus immunoglobulin, which could adversely affect operations if sales or prices decline[67]. - The pandemic has negatively affected the company's production and market activities, particularly in outdoor and field operations, leading to reduced product demand[69]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by the Shanghai Qingpu District Ecological Environment Bureau[92]. - Main pollutants include waste gas and wastewater, with waste gas primarily consisting of VOCs, odor concentration, hydrogen sulfide, and oil smoke[93]. - The company has implemented various pollution control measures, including a recovery facility for ammonium sulfate and activated carbon purification devices[94]. - Wastewater is treated through a recovery process before being discharged into the Qingpu Second Wastewater Treatment Plant[95]. - The company has established an emergency response plan for environmental incidents, which has been filed with the environmental authorities[97]. - The company conducts regular environmental monitoring, ensuring that all pollutant discharge indicators meet standards[98]. - No administrative penalties were imposed on the company during the reporting period for environmental issues[99]. - The subsidiary, Sailun Dafeng, is not classified as a key pollutant discharge unit and manages its waste through biogas treatment for agricultural irrigation[100]. Shareholder Commitments and Governance - The company has committed to a lock-up period of 36 months for its shares held by major shareholders, including Zhao Aisan and Fan Zhihe, starting from the date of listing[103]. - Major shareholders, including Zhi Yuan Investment, have also agreed to a 36-month lock-up period for their shares following the company's IPO[108]. - If the company's stock price falls below the IPO price for 20 consecutive trading days within the first 6 months post-IPO, the lock-up period will automatically extend by an additional 6 months[106]. - The company has established a long-term commitment to maintain the integrity of its shareholding structure, with various commitments from shareholders and management to not transfer shares during the lock-up period[104]. - The company has outlined that any share reduction by major shareholders within two years post-lock-up must not be below the IPO price[109]. - The commitments made by shareholders and management are designed to ensure stability and confidence in the company's stock performance post-IPO[107]. - The company has a clear strategy to manage potential conflicts of interest among major shareholders, ensuring compliance with regulatory requirements[110]. - All commitments made by shareholders and management are legally binding, with potential legal consequences for any breaches[105]. - The company has emphasized the importance of transparency in shareholding changes during the lock-up period[106]. - The commitments are aimed at fostering investor trust and maintaining a stable market environment for the company's shares[104]. Cash Management and Fund Utilization - The company raised a total of 893,791,800.00 CNY from its initial public offering, with a net amount of 784,923,575.78 CNY after deducting issuance costs[170]. - As of the reporting period, the cumulative investment of raised funds amounted to 870,600.00 CNY, representing 0.22% of the total committed investment[172]. - The company utilized 361.25 thousand CNY of its own funds for the development of special new drugs and innovative technology projects during the period[170]. - The company approved the use of up to RMB 750 million of idle raised funds for cash management, with a usage period not exceeding 12 months[175]. - The company’s cash management strategy includes the purchase of financial products, with a remaining balance of RMB 418 million as of June 30, 2022[175]. - The company plans to maintain its cash management strategy while ensuring it does not affect the investment projects funded by the raised capital[175]. Future Outlook and Strategic Goals - The company plans to enhance its core competitiveness and sustainable profitability by increasing R&D investment and improving its sales network[129]. - The company acknowledges potential risks from regulatory changes, competitive products, and cost fluctuations, and will maintain good relationships with downstream customers[129]. - The company has committed to protecting the interests of minority shareholders and ensuring that any dilution of immediate returns is addressed through various measures[133]. - The company plans to distribute at least 20% of the distributable profits as cash dividends if conditions are met[140]. - In a mature stage without significant capital expenditure, cash dividends should constitute at least 80% of the profit distribution[143]. - In a mature stage with significant capital expenditure, cash dividends should constitute at least 40% of the profit distribution[143]. - In a growth stage with significant capital expenditure, cash dividends should constitute at least 20% of the profit distribution[143]. - Significant capital expenditure is defined as transactions involving assets totaling over 30% of the latest audited net assets[144]. - The board must consider the timing, conditions, and minimum ratios for cash dividends, requiring majority approval from both the board and supervisory board[141]. - The company will actively seek feedback from minority shareholders regarding dividend proposals[141].

Financial Performance - The company plans to distribute a cash dividend of RMB 9.00 per 10 shares, totaling RMB 97,398,000, which represents 127.35% of the net profit attributable to shareholders for 2021[5]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2021 was CNY 208,693,627.46, representing a 12.47% increase compared to CNY 185,562,793.03 in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 76,482,795.73, which is a 21.07% increase from CNY 63,173,802.30 in 2020[22]. - The net profit after deducting non-recurring gains and losses was CNY 69,513,945.85, reflecting a 23.06% increase from CNY 56,488,609.44 in 2020[22]. - The basic earnings per share for 2021 was 0.94 yuan, representing a 20.51% increase from 0.78 yuan in 2020[23]. - The weighted average return on equity increased to 23.08%, up 1.94 percentage points from 21.14% in 2020[23]. - The total assets at the end of 2021 were CNY 402,891,055.95, which is a 29.07% increase from CNY 312,148,232.39 at the end of 2020[22]. - The net assets attributable to shareholders increased by 25.47% to CNY 369,629,071.96 at the end of 2021, compared to CNY 294,606,422.89 at the end of 2020[22]. - The cash flow from operating activities for 2021 was CNY 92,288,488.20, a decrease of 6.17% compared to CNY 98,354,730.48 in 2020[22]. Research and Development - The company is focused on the development of new biological emergency rescue drugs under the ATS project[13]. - The company aims to enhance its production processes to achieve higher purity and quality in its products[13]. - The company is actively involved in the research and development of immunoglobulin products for various therapeutic applications[13]. - Research and development expenses accounted for 12.34% of operating revenue, an increase of 0.21 percentage points from the previous year[24]. - The total R&D investment for the year was approximately ¥25.76 million, an increase of 14.42% from the previous year, with R&D expenses accounting for 12.34% of total revenue[67]. - The company has developed core proprietary technologies for the safe and effective production of emergency treatment drugs, including toxin proteomics research and antigen purification technology[61]. - The company has established a structured governance framework to ensure effective decision-making and protect shareholder interests[137]. - The company has 12 ongoing research projects, including the development of antivenoms and immunoglobulins, with expected total investments ranging from 620.00 million RMB to 8,000.00 million RMB[69]. - The company has received 4 new invention patents during the reporting period, bringing the total number of granted patents to 12[65]. Market Position and Strategy - The company is committed to expanding its market presence and enhancing its product offerings in the biopharmaceutical sector[13]. - The biopharmaceutical market in China is expected to reach RMB 1,319.8 billion by 2030, with a compound annual growth rate (CAGR) of 10.9% from 2023 to 2030[48]. - The company is currently the only producer of antivenom serum and equine tetanus immunoglobulin in China, holding a unique market position[52]. - The company aims to become a leading enterprise in the field of biotoxin and biosafety drug development, focusing on the research and development of various types of antivenoms[38]. - The company has established a comprehensive marketing team covering the entire industry chain from research and development to production and sales[38]. - The company is focusing on strategic acquisitions to enhance its technology capabilities, targeting two potential companies by Q2 2024[151]. Operational Risks and Governance - The company has detailed various operational risks in the report, which investors should review[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors[6]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with a majority of directors being unable to ensure the accuracy and completeness of the annual report[8]. - The company has established a comprehensive internal control system to ensure effective governance and management, covering major investments, related transactions, and external guarantees[174]. - The company has a solid governance structure involving the shareholders' meeting, board of directors, independent directors, supervisory board, and senior management[174]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit, implementing various measures to manage waste gas and wastewater effectively[178]. - The company has established an environmental monitoring plan, ensuring that all pollution indicators meet the required standards through third-party testing[183]. - The company has implemented automatic online monitoring for wastewater discharge, ensuring real-time compliance with environmental standards[187]. - The company has actively improved product quality standards, adding new quality control projects for its anti-five-step snake venom serum[37]. - The company has established emergency response plans for environmental incidents, with regular training for employees to enhance crisis management capabilities[182]. - The company actively participates in social responsibility initiatives, including building a rescue network for snakebite patients[177]. Employee and Management - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to RMB 6.1287 million[154]. - The company has implemented a competitive and incentive-based salary policy to enhance employee motivation and performance[166]. - Employee benefits include free lunch, dormitory accommodations, free shuttle service, high-temperature allowances, annual health check-ups, holiday benefits, birthday benefits, and special benefits for female employees[167]. - The company emphasizes employee training across various aspects, including professional skills and knowledge, to enhance overall competency and retain talent[168]. - The company employed a total of 295 staff members, with 230 in the parent company and 65 in major subsidiaries[165]. Product Development and Quality Control - The company has established a comprehensive quality management system in compliance with GMP, ensuring product quality throughout the entire lifecycle[200]. - The company has a robust after-sales service system, including regular follow-ups and a user complaint management procedure[199]. - All sales drugs have obtained necessary registration certificates, with no administrative penalties due to quality issues reported during the period[200]. - The company has implemented a supplier evaluation and approval system to ensure quality and compliance of raw materials and components[199]. - The company has upgraded the production process of traditional tetanus antitoxin to improve purity and reduce adverse reaction rates, which is a necessary trend in the industry[60].

2022 年第一季度报告 证券代码：688163 证券简称：赛伦生物 上海赛伦生物技术股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年 | | --- | --- | --- | --- | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 24,903,036.81 | 12.04 | | 归属于上市公司股东的净利润 | | 3,959,971.69 | 15.87 | | 归属于上市公司股东的扣除非 | | 3,4 ...